This MedLibrary.org supplementary page on Serotonin-noradrenaline-dopamine reuptake inhibitor is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
Serotonin-norepinephrine-dopamine-reuptake-inhibitors (SNDRI) are a class of psychoactive antidepressants. They act upon neurotransmitters in the brain, namely, serotonin, norepinephrine and dopamine. These three biogenic monoamines are associated with depression and increasing the availability in the brain is one method used to treat the condition.
SNDRIs are so-called triple reuptake inhibitors, which elevate extracellular plasma concentrations of all three monoamine neurotransmitters, serotonin, norepinephrine and dopamine in the synaptic cleft. These compounds show high potency but low selectivity between the different monoamine transporter proteins. No SNDRIs are yet on the market, although the first of these agents tesofensine is currently in clinical trials,12 and other compounds such as brasofensine3 and GlaxoSmithKline's NS23594 are under development.
It should be noted that some SNRI drugs such as Venlafaxine (Effexor) and Sibutramine (Meridia/Reductil) are known to weakly inhibit the reuptake of dopamine at high doses, and so while these drugs are selective for the serotonin and noradrenaline transporters at normal doses, they can start to act as SNDRIs when taken at doses above the normal therapeutic range.
References
- ^ "Tesofensine". Retrieved on 2007-08-20.
- ^ Lehr T, Staab A, Tillmann C, et al (2007). "Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease". British journal of clinical pharmacology 64 (1): 36–48. doi:. PMID 17324246.
- ^ Pearce RK, Smith LA, Jackson MJ, Banerji T, Scheel-Krüger J, Jenner P (2002). "The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosets". Mov. Disord. 17 (5): 877–86. doi:. PMID 12360536.
- ^ NS2359
External links
- www.biopsychiatry.com/antidepressants/triple.html
- www.drugresearcher.com/news/ng.asp?id=61172-antidepressant-glaxosmithkline-merck
- www.currentpsychiatry.com/article_pages.asp?AID=4795
 |
This medical article is a stub. You can help Wikipedia by expanding it. |
|
|||||||||||||||||||||||||||||||
Wikipedia content modification information:
- This page was last modified on 7 October 2008, at 01:57.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Serotonin-noradrenaline-dopamine reuptake inhibitor".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.